

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

Rad51 (D4B10) Rabbit mAb

RRID:AB_2721109

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 8875, RRID:AB_2721109

Antibody Information

URL: http://antibodyregistry.org/AB_2721109

Proper Citation: Cell Signaling Technology Cat# 8875, RRID:AB_2721109

Target Antigen: RAD51

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP

Antibody Name: Rad51 (D4B10) Rabbit mAb

Description: This monoclonal targets RAD51

Target Organism: monkey, rat, mouse, human

Antibody ID: AB_2721109

Vendor: Cell Signaling Technology

Catalog Number: 8875

Record Creation Time: 20231110T033730+0000

Record Last Update: 20260829T143636+0000

Ratings and Alerts

No rating or validation information has been found for Rad51 (D4B10) Rabbit mAb.

No alerts have been found for Rad51 (D4B10) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 36 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Singh G, et al. (2026) miR-181d coordinates homologous recombination and anti-tumor immune responses in glioblastoma. *iScience*, 29(3), 115077.

Wang D, et al. (2026) PRMT5 is Frequently Upregulated and a Potential Therapeutic Target in MTAP-deficient Malignant Peripheral Nerve Sheath Tumors. *bioRxiv : the preprint server for biology*.

Singh D, et al. (2026) Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Antitumor Immunity. *Cancer research*, 86(5), 1252.

Gu JJ, et al. (2026) ABL kinase inactivation induces transcription-replication conflicts and impairs replication fork progression in metastatic small cell lung cancer. *Cell reports*, 45(7), 117699.

Avolio M, et al. (2026) The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer. *Cancer discovery*, 16(2), 270.

Sottnik JL, et al. (2026) Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP Inhibition. *Cancer research*, 86(7), 1605.

Tan GYT, et al. (2026) BMAL2 is a druggable target for ovarian clear cell carcinoma (OCCC). *EMBO molecular medicine*, 18(5), 1933.

Chiang JC, et al. (2025) Lipoylation inhibition enhances radiation control of lung cancer by suppressing homologous recombination DNA damage repair. *Science advances*, 11(11), eadt1241.

Xiao Q, et al. (2025) Combined MEK and PARP inhibition enhances radiation response in rectal cancer. *Cell reports. Medicine*, 6(8), 102284.

Musiani D, et al. (2025) Uracil processing by SMUG1 in the absence of UNG triggers homologous recombination and selectively kills BRCA1/2-deficient tumors. *Molecular cell*, 85(6), 1072.

Okechukwu CC, et al. (2025) CF10 Displayed Improved Activity Relative to 5-FU in a Mouse CRLM Model Under Conditions of Physiological Folate. *Cancers*, 17(17).

Boucher J, et al. (2025) CDK12 inhibition reveals melanoma dependence on the RUNX1/CBF?? complex for genomic stability. *Cell reports*, 44(11), 116495.

Deans-Fielder K, et al. (2024) Mechanisms driving fasting-induced protection from genotoxic injury in the small intestine. *American journal of physiology. Gastrointestinal and liver physiology*, 326(5), G504.

Sellars E, et al. (2024) A high-throughput approach to identify BRCA1-downregulating compounds to enhance PARP inhibitor sensitivity. *iScience*, 27(7), 110180.

Rageul J, et al. (2024) Poly(ADP-ribosyl)ation of TIMELESS limits DNA replication stress and promotes stalled fork protection. *Cell reports*, 43(3), 113845.

Pan Q, et al. (2024) Mapping functional elements of the DNA damage response through base editor screens. *Cell reports*, 43(12), 115047.

Fukuda K, et al. (2024) Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations. *Cell reports. Medicine*, 5(6), 101578.

Son MY, et al. (2024) RAD51 separation of function mutation disables replication fork maintenance but preserves DSB repair. *iScience*, 27(4), 109524.

Hanthi YW, et al. (2024) RAD51 protects abasic sites to prevent replication fork breakage. *Molecular cell*, 84(16), 3026.

Simoni-Nieves A, et al. (2024) A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib. *Cell reports. Medicine*, 5(9), 101703.